The CME Group sued the Commodity Futures Trading Commission on Thursday, accusing the regulator of getting it wrong when it approved Kalshi's first U.S. perpetual futures product. The lawsuit, filed in federal court, challenges the legal basis of the CFTC's green light for the contract, a move that pits one of the world's largest derivatives exchanges against its own watchdog.
The Lawsuit's Core Argument
CME's complaint centers on how the CFTC evaluated Kalshi's application. The exchange argues that the agency's approval process was flawed — that the CFTC misinterpreted its own rules or overlooked key legal questions when it let Kalshi launch the product. Perpetual futures, unlike standard futures, have no expiration date, which can make them behave more like spot markets. CME claims that distinction matters and that the CFTC failed to properly account for it.
Legal experts following the case say the outcome could reshape how new derivatives products get cleared in the U.S. But the lawsuit itself offers no quotes from CME executives or CFTC officials. The filing speaks for itself: a formal demand that a court review the agency's decision.
What Kalshi's Product Means
Kalshi, a platform known for event-based contracts, received CFTC approval for its first perpetual futures product earlier this year. The exact terms of that approval aren't public in detail, but the product allows traders to hold positions indefinitely, as long as they maintain margin. That's a big deal for a company that until now focused on binary event contracts — yes-or-no bets on things like inflation or election outcomes.
By adding perpetual futures, Kalshi steps onto turf long dominated by crypto exchanges like Binance and BitMEX. But those platforms operate largely offshore. Kalshi's product, by contrast, is CFTC-regulated, which gives it a stamp of legitimacy — and, CME argues, a competitive advantage gained through a regulatory shortcut.
Why CME Is Challenging the Approval
CME itself offers a range of futures products, including Bitcoin futures and micro contracts. It's no secret that a regulated perpetual futures product from Kalshi could siphon trading volume from CME's own offerings. But the lawsuit doesn't mention market share or competition. Instead, it frames the dispute as a matter of administrative law: Did the CFTC follow the right procedure?
The exchange wants the court to vacate the approval, which would force Kalshi to halt trading in the product. That's a high-stakes ask, and the CFTC will almost certainly defend its decision. The agency rarely loses in court, but the case raises questions about how much discretion the CFTC has when approving novel products.
For now, Kalshi continues to operate the perpetual futures contract. A hearing on the lawsuit hasn't been scheduled. The case will unfold in the coming months, with both sides filing briefs and, possibly, seeking a preliminary injunction.
